Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Fungal Allergenic Extract [EPC]
Candida Tropicalis is a non-standardized fungal allergenic extract used primarily for the diagnosis and treatment of IgE-mediated allergic reactions and as a diagnostic tool for assessing cell-mediated immunity.
Name
Candida Tropicalis
Raw Name
CANDIDA TROPICALIS
Category
Non-Standardized Fungal Allergenic Extract [EPC]
Drug Count
8
Variant Count
8
Last Verified
February 17, 2026
About Candida Tropicalis
Candida Tropicalis is a non-standardized fungal allergenic extract used primarily for the diagnosis and treatment of IgE-mediated allergic reactions and as a diagnostic tool for assessing cell-mediated immunity.
Detailed information about Candida Tropicalis
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Candida Tropicalis.
As a 'non-standardized' extract, Candida Tropicalis does not have a federally mandated potency unit (such as the Bioequivalent Allergy Unit or BAU used for grasses or dust mites). Instead, its potency is typically expressed in terms of weight-to-volume (w/v) ratios or Protein Nitrogen Units (PNU). This classification means that the biological activity may vary between different manufacturers, necessitating cautious titration by healthcare providers. The FDA has permitted the use of these extracts for decades, primarily based on their historical use in clinical allergy practice for the diagnosis of fungal hypersensitivity and the formulation of subcutaneous immunotherapy (allergy shots).
The mechanism of action for Candida Tropicalis depends on whether it is being used for diagnosis or therapy. At the molecular level, the extract contains various proteins and polysaccharides that act as antigens. When used in diagnostic skin testing, the extract is introduced into the skin (percutaneously or intradermally). If the patient has pre-existing IgE antibodies specific to Candida Tropicalis, these antibodies—which are bound to the surface of mast cells—recognize the antigen. This recognition triggers mast cell degranulation, releasing histamine, leukotrienes, and other inflammatory mediators. This results in a 'wheal and flare' reaction (a raised bump and surrounding redness), which is measured by the clinician to determine the level of sensitivity.
In immunotherapy, the mechanism shifts toward immune modulation. By administering gradually increasing doses of the Candida Tropicalis extract over months or years, the healthcare provider attempts to induce 'immunological tolerance.' This process involves a shift from a Th2-dominated immune response (which promotes IgE and allergy) to a Th1-dominated or T-regulatory (Treg) response. This leads to the production of 'blocking antibodies' (IgG4) that compete with IgE for the allergen, effectively dampening the allergic cascade upon future environmental exposure.
Because Candida Tropicalis extracts are biological proteins administered locally (topically on the skin or subcutaneously), they do not follow traditional small-molecule pharmacokinetics.
Candida Tropicalis allergenic extract is indicated for several specific clinical scenarios:
Candida Tropicalis is typically available in the following formats:
> Important: Only your healthcare provider can determine if Candida Tropicalis is right for your specific condition. Testing and treatment must be performed in a clinical setting equipped to handle emergency allergic reactions.
Dosage for Candida Tropicalis is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels.
Candida Tropicalis extracts are used in children, but the dosing must be approached with extreme caution due to the higher risk of systemic reactions in pediatric populations. Dosage is generally determined by the same titration method used in adults, but the starting dose may be even more conservative. There is no specific age cutoff, but testing is often deferred in very young infants unless clinically necessary.
No specific dosage adjustments are required for patients with kidney disease, as the systemic load of the protein extract is negligible.
No dosage adjustments are necessary for patients with liver disease.
Older adults may have reduced skin reactivity, which can lead to false-negative results in diagnostic testing. Furthermore, elderly patients on beta-blockers for cardiovascular conditions are at higher risk if an emergency reaction occurs, requiring careful dose selection.
Candida Tropicalis extracts are never self-administered by the patient at home. They must be administered by a trained healthcare professional in a medical office.
In immunotherapy, consistency is vital. If a dose is missed:
An overdose of Candida Tropicalis extract typically manifests as a severe systemic allergic reaction (anaphylaxis). Signs include hives, swelling of the throat, wheezing, and a drop in blood pressure.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.
Most patients undergoing testing or treatment with Candida Tropicalis will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Candida Tropicalis and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
With prolonged immunotherapy (3–5 years), the most common long-term effect is the successful reduction of allergy symptoms. However, some patients may develop a persistent nodule (granuloma) at the injection site if the extract is not injected deeply enough into the subcutaneous tissue. There is no evidence that long-term use of fungal extracts increases the risk of cancer or autoimmune disease.
While Candida Tropicalis itself may not always carry a specific brand-name black box warning, the entire class of allergenic extracts carries a de facto warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider immediately. Even a mild systemic reaction (like a few hives) must be reported before your next dose, as it may predict a more severe reaction in the future.
Candida Tropicalis allergenic extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic purposes under the direct supervision of a physician. It is not an antifungal medication and should not be used to treat active fungal infections like candidiasis (thrush or vaginal yeast infections).
No specific FDA black box warning exists for the generic 'Candida Tropicalis' extract, but manufacturers of allergenic extracts (such as Greer or Jubilant HollisterStier) include prominent warnings that these products can cause severe, life-threatening systemic reactions, including anaphylaxis. These reactions can occur even in patients who have previously tolerated the extract without issue.
Most patients can drive after the 30-minute observation period. However, if you experience dizziness, fatigue, or any signs of a systemic reaction, do not operate machinery and notify your doctor immediately.
Alcohol consumption should be avoided for several hours before and after receiving an injection. Alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption and heighten the risk or severity of a systemic reaction.
If immunotherapy is discontinued, the patient’s sensitivity to Candida Tropicalis may eventually return to its baseline level. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the therapeutic benefits (allergy relief) will gradually diminish over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Candida Tropicalis.
There are no drugs that are strictly 'contraindicated' in the sense of a chemical incompatibility, but certain drugs make the use of Candida Tropicalis dangerously unsafe:
There are no known direct food interactions with Candida Tropicalis extract. However, patients should avoid heavy meals or very spicy foods immediately before an injection, as these can sometimes mimic or mask the early signs of an allergic reaction (such as flushing or GI upset).
Candida Tropicalis extract will not affect standard blood work (like a CBC or metabolic panel). However, it will directly affect:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Candida Tropicalis extract must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients allergic to Candida tropicalis often show cross-reactivity with other Candida species, such as Candida albicans or Candida glabrata. There may also be minor cross-reactivity with other taxonomic fungi in the Ascomycota phylum, such as Saccharomyces cerevisiae (Baker's yeast). If you have a known severe allergy to any yeast, inform your doctor.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Candida Tropicalis.
FDA Pregnancy Category C. There are no adequate and well-controlled studies of Candida Tropicalis extract in pregnant women.
It is not known whether Candida Tropicalis antigens are excreted in human milk. However, because the proteins are digested in the mother's system and the dose is minimal, it is generally considered safe to continue maintenance immunotherapy while breastfeeding. Caution is advised during the build-up phase.
Candida Tropicalis is used in children for both diagnosis and treatment. However, children under the age of 5 may have difficulty cooperating with the 30-minute observation period and may not be able to articulate the early symptoms of a systemic reaction (such as an itchy throat). Pediatric use is typically reserved for children with significant symptoms that cannot be managed by other means.
In patients over 65, the skin's reactivity to allergens decreases due to physiological changes in the dermis. This can lead to smaller wheal sizes during testing. Furthermore, the prevalence of cardiovascular disease and the use of beta-blockers in this population make the management of potential anaphylaxis more complex. A more conservative dosing approach is often used.
No dose adjustment is needed for patients with renal impairment. The fungal proteins are not nephrotoxic and are administered in microgram quantities.
No dose adjustment is needed for patients with hepatic impairment. The liver is not the primary site of clearance for these biological extracts.
> Important: Special populations require individualized medical assessment.
Candida Tropicalis extract works as an immunomodulator. In diagnostic use, it cross-links IgE antibodies on the surface of mast cells, leading to the release of pre-formed mediators like histamine. In therapeutic use (immunotherapy), it induces a state of desensitization. This is achieved by increasing the production of T-regulatory cells and IL-10, which suppress the allergic Th2 response. Over time, the body produces IgG4 'blocking' antibodies, which prevent the allergen from binding to IgE, thus stopping the allergic reaction at its source.
| Parameter | Value |
|---|---|
| Bioavailability | Low (Local subcutaneous absorption) |
| Protein Binding | N/A (Biological proteins) |
| Half-life | Minutes to hours (Proteolysis) |
| Tmax | 1–2 hours (Systemic absorption) |
| Metabolism | Tissue Proteases |
| Excretion | Renal (Metabolites) |
Candida Tropicalis belongs to the class of Non-Standardized Fungal Allergenic Extracts. It is grouped with other fungal extracts like Alternaria, Cladosporium, and Aspergillus. Unlike standardized extracts (e.g., Cat Hair or Ragweed), its potency is determined by the manufacturer's internal standards rather than a universal FDA reference standard.
Common questions about Candida Tropicalis
Candida Tropicalis extract is primarily used as a diagnostic tool to identify fungal allergies through skin testing and as a treatment in the form of allergy shots (immunotherapy). When used for testing, it helps doctors determine if a patient's respiratory symptoms, such as asthma or hay fever, are triggered by sensitivity to this specific yeast. In immunotherapy, small, increasing doses are injected under the skin to help the immune system build a tolerance to the fungus. Additionally, it has been used historically as a 'recall antigen' to test whether a patient's cellular immune system is functioning correctly. It is not used to treat active yeast infections like thrush.
The most common side effects are local reactions at the site of the skin test or injection, which occur in a majority of patients. These typically include redness, itching, and a raised bump known as a wheal, similar to a mosquito bite. Some patients may experience a 'large local reaction' where the swelling spreads several inches across the arm and lasts for a day or two. While these local effects are bothersome, they are generally not dangerous. However, because it is an allergen, there is always a small risk of a serious systemic reaction like hives or difficulty breathing. Your doctor will monitor you for at least 30 minutes after each administration to ensure your safety.
It is generally advised to avoid alcohol for several hours before and after receiving a Candida Tropicalis injection or undergoing skin testing. Alcohol can cause your blood vessels to dilate (expand), which might increase the speed at which the allergen is absorbed into your bloodstream. This could potentially increase the risk of a systemic allergic reaction or make a reaction more severe if one occurs. Furthermore, alcohol can sometimes cause flushing or lightheadedness that might be confused with the early signs of anaphylaxis. To ensure the most accurate testing and the safest treatment, it is best to remain sober on the day of your appointment.
The use of Candida Tropicalis extracts during pregnancy is approached with significant caution. Doctors generally do not start new allergy testing or begin the 'build-up' phase of immunotherapy in pregnant women because of the risk of a severe allergic reaction, which could deprive the fetus of oxygen. However, if a woman is already on a stable maintenance dose of allergy shots and is tolerating them well, many allergists will continue the treatment at that same dose throughout pregnancy. The decision is based on a risk-benefit analysis, as maintaining control over asthma and allergies is also important for a healthy pregnancy. Always inform your allergist immediately if you become pregnant.
If you are using Candida Tropicalis for diagnostic skin testing, the results are almost immediate, appearing within 15 to 20 minutes of application. However, if you are receiving the extract as part of an immunotherapy program (allergy shots), the process is much slower. Most patients do not notice a significant decrease in their allergy symptoms until they reach their 'maintenance dose,' which usually takes 3 to 6 months of weekly injections. Full clinical benefit is typically realized after 12 months of treatment. A full course of immunotherapy usually lasts 3 to 5 years to provide long-lasting protection against allergic triggers.
Yes, you can stop receiving Candida Tropicalis injections at any time without experiencing physical withdrawal symptoms, as it is not an addictive or habit-forming medication. However, stopping the treatment prematurely—especially before you have completed 3 to 5 years of therapy—usually means that your allergy symptoms will eventually return. The 'tolerance' that the shots build up in your immune system requires consistent exposure to maintain. If you miss several doses due to illness or travel, your doctor will likely need to reduce your dose when you return to ensure you don't have a reaction. Always discuss your treatment plan with your allergist before stopping.
If you miss a scheduled immunotherapy injection of Candida Tropicalis, you should contact your allergist's office as soon as possible to reschedule. Missing a dose for a week or two usually just requires repeating the last successful dose. However, if you miss several weeks, your immune system's sensitivity may have changed, and giving the next scheduled higher dose could be dangerous. In such cases, your doctor will follow a specific 'back-off' schedule, reducing the concentration of the extract to safely restart your build-up. Never attempt to 'double up' on doses to make up for a missed appointment, as this significantly increases the risk of anaphylaxis.
There is no clinical evidence to suggest that Candida Tropicalis allergenic extracts cause weight gain. Unlike systemic corticosteroids (like prednisone) which are known to affect metabolism and appetite, allergenic extracts are biological proteins administered in very tiny amounts. They work locally with your immune cells and do not have the systemic hormonal effects that lead to weight changes. If you experience weight gain while on immunotherapy, it is likely due to other factors, such as other medications you may be taking for asthma or unrelated lifestyle changes. You should discuss any concerns about weight with your primary care physician.
Candida Tropicalis can be administered alongside most medications, but there are critical exceptions. You must tell your doctor if you are taking beta-blockers (often used for blood pressure or heart issues), as these can make emergency treatment for an allergic reaction less effective. Additionally, you must stop taking antihistamines (like Zyrtec or Claritin) and certain antidepressants (like Amitriptyline) several days before skin testing, as these drugs will block the allergic response and lead to inaccurate results. Most other routine medications for cholesterol, diabetes, or birth control do not interact with allergenic extracts. Always provide your allergist with a complete and updated list of your medications.
Candida Tropicalis is a biological extract rather than a synthetic drug, so the term 'generic' is used slightly differently. It is produced by several different biological laboratories (such as Greer Laboratories or Jubilant HollisterStier). While these are essentially the same active ingredient, they are considered 'non-standardized,' meaning the exact protein concentration can vary between manufacturers. Therefore, your allergist will usually stick with one manufacturer's product for your entire course of treatment. If they must switch brands, they will typically reduce your dose significantly to ensure safety, as the new brand might be more potent than the previous one.